Vi­a­tris plans for Ozem­pic, We­govy gener­ics amid law­suit from No­vo Nordisk over We­govy

Last year
Pharma

Ab­b­Vie dou­bles down on cor­po­rate aware­ness ef­forts in lat­est so­cial and dig­i­tal cam­paign

Last year
Pharma
Marketing

Gink­go Bioworks nets sec­ond con­tract with Mer­ck

Last year
Deals
Manufacturing

Ar­cus de­pri­or­i­tizes Gilead-part­nered drug in prostate can­cer, the lat­est hic­cup in $1.6B col­lab­o­ra­tion

Last year
R&D

Sage sug­gests job and pipeline cuts af­ter FDA re­jec­tion of ma­jor de­pres­sion pill

Last year
People
Pharma

BioN­Tech ex­pands ADC deal with Du­al­i­ty­Bio; Gra­cell and IO Biotech get pri­vate place­ments from a slew of in­vestors

Last year
News Briefing

Po­sei­da lines up an­oth­er al­lo­gene­ic CAR-T part­ner, al­ly­ing with Astel­las on sol­id tu­mors

Last year
Financing
Cell/Gene Tx

Ike­na inks small cash grab in all-stock deal for Pi­o­nyr to take can­cer drug on Hip­po path­way

Last year
Startups
Deals

Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Last year
R&D

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
R&D
Pharma

Bavar­i­an Nordic makes plans to sub­mit chikun­gun­ya vac­cine for ap­proval af­ter sec­ond pos­i­tive PhI­II tri­al read­out

Last year
R&D

FDA ap­proves sec­ond ge­o­graph­ic at­ro­phy drug but caps use pe­ri­od, as Astel­las’ Iver­ic looks to spar with Apel­lis

Last year
Pharma
FDA+

FDA clears Bio­gen, Sage's pill for post­par­tum de­pres­sion; What will Roivant, Bridge­Bio do next?; EQRx be­comes ...

Last year
Weekly

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Last year
R&D
Pharma

Te­va agrees ‘in prin­ci­ple’ to $175M opi­oid set­tle­ment to hos­pi­tals and health sys­tems

Last year
Pharma
Law

New FDA guid­ance gives man­u­fac­tur­ers lim­its for ni­trosamines

Last year
Pharma
FDA+

CDC vac­cine com­mit­tee votes unan­i­mous­ly to rec­om­mend Sanofi and As­traZeneca's RSV im­mu­niza­tion for ba­bies

Last year
Pharma
Marketing

House E&C chair racks up cam­paign con­tri­bu­tions from more than 30 bio­phar­ma com­pa­nies so far in 2023

Last year
People
FDA+

BAR­DA or­ders more small­pox and mpox vac­cines from Bavar­i­an Nordic

Last year
Deals
Pharma

Pfiz­er places a dozen prod­ucts on emer­gency or­der af­ter tor­na­do dam­age at North Car­oli­na plant

Last year
Pharma

Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Last year
Startups
R&D

De­tails emerge on Cidara/J&J in­fluen­za part­ner­ship, with a count­down on next steps

Last year
Deals
Pharma

Terns Phar­ma­ceu­ti­cal­s' CEO Senthil Sun­daram steps down for health rea­sons

Last year
People

As Ver­tex’s piv­otal pain read­out looms, non-opi­oid drug de­vel­op­ment faces a reck­on­ing

Last year
R&D
In Focus
First page Previous page 300301302303304305306 Next page Last page
A service from the Financial Times